BackgroundThe clinical context for using blood eosinophil (EOS) counts as treatment-response biomarkers in asthma and chronic obstructive pulmonary disease (COPD) requires better understanding of EOS distributions and ranges. We describe EOS distributions and ranges published in asthma, COPD, control (non-asthma/COPD) and general populations.MethodsWe conducted a comprehensive literature review and meta-analysis of observational studies (Jan 2008 to Nov 2018) that included EOS counts in asthma, severe asthma, COPD, control and general populations. Excluded studies had total sample sizes <200, EOS as inclusion criterion, hospitalised population only, exclusively paediatric participants.ResultsOverall, 91 eligible studies were identified, most had total-population-level data available: asthma (n=39 studies), severe asthma (n=12 studies), COPD (n=23 studies), control (n=7 studies), general populations (n=14 studies); some articles reported data for multiple populations. Reported EOS distributions were right-skewed (n=7 studies). Reported median EOS counts ranged from: asthma, 157–280 cells·µL−1 (n=22 studies); severe asthma, 200–400 cells·µL−1 (n=8 studies); COPD, 150–183 cells·µL−1 (n=6 studies); controls, 100–160 cells·µL−1 (n=3 studies); general populations, 100–200 cells·µL−1 (n=6 studies). The meta-analysis showed observed variability was mostly between studies rather than within studies. Factors reportedly associated with higher blood EOS counts included: current smoking, positive skin prick test, elevated total IgE, comorbid allergic rhinitis, age ≤18 years, male sex, spirometric asthma/COPD diagnosis, metabolic syndrome and adiposity.ConclusionEOS distribution and range varied by study population, and were affected by clinical factors including age, smoking history and comorbidities which, regardless of severity, should be considered during treatment decision making.